Lisa A. Carey, MD

Articles

Dr. Carey on the Clinical Implications of the FeDeriCa trial in HER2+ Breast Cancer

July 8th 2021

Lisa A. Carey, MD, FASCO, discusses the clinical implications of the phase 3 FeDeriCa trial in HER2-positive breast cancer.

Dr. Carey Discusses Findings From the CALGB40502 Trial in TNBC

February 7th 2018

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses findings from the CALGB 40502/NCCTG N063H trial in triple-negative breast cancer.

Dr. Carey Discusses the CALGB40502 Trial in TNBC

January 30th 2018

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer (TNBC).

Dr. Carey on De-Escalating Treatments for Triple-Negative Breast Cancer

May 8th 2017

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).

Dr. Carey on Tailoring Treatment in Triple-Negative Breast Cancer

March 20th 2017

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

Dr. Carey on Treating Triple-Negative Breast Cancer

February 28th 2015

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Dr. Carey Discusses Treatment Challenges in TNBC

December 4th 2014

Lisa A. Carey, MD, the Division Chief of Hematology and Oncology at the University of North Carolina and the Physician-in-Chief at North Carolina Cancer Hospital, discusses triple-negative breast cancer (TNBC) and the importance of understanding how it differs from other types of breast cancer.

Dr. Carey on the Future of Clinical Trial Design

May 2nd 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the present and future state of clinical trial design.

Dr. Carey on Everolimus in Metastatic Breast Cancer

April 5th 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the use of everolimus in the metastatic and adjuvant settings of breast cancer.

Dr. Lisa A. Carey Discusses Psycho-Oncology

March 8th 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the field of psycho-oncology.

Dr. Carey Discusses the Need for Targeted Therapy in TNBC

April 26th 2011

Dr. Lisa Carey Discusses the Need for Targeted Therapy in Triple Negative Breast Cancer (TNBC)